Fresenius USA complaint handling procedures are inadequate -- FDA warning letter.
This article was originally published in The Gray Sheet
Executive Summary
FRESENIUS USA HEMODIALYZER/REPROCESSOR UNANTICIPATED DEVICE FAILURES should have been categorized by the company as complaints and investigated pursuant to good manufacturing practices (GMP) requirements, FDA says in a May 25 warning letter to the Walnut Creek, California-based firm. Review of service repair records for 40 Model 2008E and 55 Model 2008H hemodialysis machines, manufactured between March 1993 and March 1994, "showed at least 30 unanticipated device failures which were not identified, reviewed or evaluated as complaints," FDA says. In addition, review of service repair records for five Fresenius DRS-4 dialyzer reprocessing systems "found at least 11 reports of unanticipated device failures" that were not treated as complaints.
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.